IRVINGTON, N.Y., Nov. 5, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of MelaFind®, a non-invasive software-driven image analysis device intended to provide a dermatologist with objective data of clinically irregular pigmented moles when they choose to obtain additional info to help them decide whether or not to biopsy (at the most curable and cost-effective stage), will release third quarter 2014 financial results on Wednesday, November 12, after the market close. MELA Sciences President and Chief Executive Officer, Rose Crane, and Robert Cook, Chief Financial Officer, will host a conference call at 4:30pm Eastern Time to review the Company's progress and answer questions.
Conference Call Details:
| Date: | Wednesday, November 12, 2014 |
| Time: | 4:30 p.m. Eastern Time |
| Toll Free: | 800-481-9591 |
| International: | 719-325-2356 |
| Passcode: | 7718908 |
| Webcast: | http://public.viavid.com/player/index.php?id=111559 |
Replays, Available through November 26:
| Toll Free: | 877-870-5176 |
| International: | 858-384-5517 |
| Replay PIN: | 7718908 |
About MELA Sciences, Inc. www.melasciences.com
MELA Sciences is a medical technology company dedicated to designing and developing innovative software-driven technologies that assist physicians during the clinical evaluation and detection of skin cancer. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for its flagship product, MelaFind®.